Gene Therapy offers real hope to people affected by LCA RDH12. It is one of the most promising frontiers of modern medicine and involves injecting a healthy copy of the missing gene in the eye.
In 2018 the first Gene Therapy for LCA (gene RP65) was approved in the USA and Europe and showed successful sight restoration in the treated patients.
This is not available for the RDH12 gene but it means that there IS concrete hope. Our goal is for Gene Therapy to be accessible to more patients with LCA including RDH12.
Eyes on the Future is partnering with the key academic and industry partners working on RDH12 gene therapy.
In July 2025, as part of the Global RDH12 Alliance, we signed a landmark partnership with Opus Genetics, a clinical-stage biopharmaceutical company developing treatments for inherited retinal diseases. Together, we are co-developing a first-in-class gene therapy designed specifically for RDH12 Inherited Retinal Dystrophy.
This innovative patient–industry collaboration will accelerate progress towards clinical trials, bringing us closer than ever to a treatment for children with RDH12. It represents a breakthrough not only for our community, but also as a pioneering model of how patients and industry can work together to drive progress in other rare diseases.
Under the agreement, the Alliance will contribute up to $1.6 million towards the development of the RDH12 programme. The partnership also includes a risk-sharing structure and performance-based milestones, with both parties jointly developing the clinical and regulatory strategy needed to take this therapy from the laboratory into the clinic.